New study tracks safety of VYLOY in everyday cancer care

NCT ID NCT06902545

Recruiting now Disease control Sponsor: Astellas Pharma Korea, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's safety in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zolbetuximab (VYLOY)
What this could lead to: If successful, this study will confirm the safety of VYLOY in everyday use, supporting its continued approval for advanced gastric and GEJ cancer.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects may still occur, and results may not apply outside South Korea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER METASTATIC GASTRIC ADENOCARCINOMA OR CANCER METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA

Contacts and locations

Locations

KR82001
RECRUITING

Seoul, South Korea
KR82002
RECRUITING

Seoul, South Korea
KR82003
RECRUITING

Seoul, South Korea
KR82004
RECRUITING

Seoul, South Korea
KR82005
RECRUITING

Seoul, South Korea
KR82006
RECRUITING

Yangsan, Gyeongsangnam-do, South Korea
KR82007
RECRUITING

Seoul, South Korea
KR82008
RECRUITING

Suwon, Gyeonggi-do, South Korea
KR82009
RECRUITING

Suwon, Gyeonggi-do, South Korea
KR82010
RECRUITING

Goyang-si, Gyeonggi-do, South Korea
KR82011
RECRUITING

Seoul, South Korea
KR82012
RECRUITING

Hwasun Gun, Jeollanam-do, South Korea
KR82013
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.